BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takahashi EA, Kallmes DF, Mara KC, Harmsen WS, Misra S. Nephrotoxicity of gadolinium-based contrast in the setting of renal artery intervention: retrospective analysis with 10-year follow-up. Diagn Interv Radiol 2018;24:378-84. [PMID: 30406762 DOI: 10.5152/dir.2018.18172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Costelloe CM, Amini B, Madewell JE. Risks and Benefits of Gadolinium-Based Contrast-Enhanced MRI. Seminars in Ultrasound, CT and MRI 2020;41:170-82. [DOI: 10.1053/j.sult.2019.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Tamanoi F, Matsumoto K, Doan TLH, Shiro A, Saitoh H. Studies on the Exposure of Gadolinium Containing Nanoparticles with Monochromatic X-rays Drive Advances in Radiation Therapy. Nanomaterials (Basel) 2020;10:E1341. [PMID: 32660093 DOI: 10.3390/nano10071341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
3 Boehm IB. Classification of gadolinium-based contrast agents (GBCAs)-adverse reactions. Magn Reson Imaging 2022;85:1-2. [PMID: 34662698 DOI: 10.1016/j.mri.2021.10.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Costelloe CM, Amini B, Madewell JE. WITHDRAWN: Risks and Benefits of Gadolinium-Based Contrast Enhanced MRI. Semin Ultrasound CT MR 2020;41:260-74. [PMID: 32446435 DOI: 10.1053/j.sult.2020.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Weng W, Biesiekierski A, Li Y, Dargusch M, Wen C. A review of the physiological impact of rare earth elements and their uses in biomedical Mg alloys. Acta Biomater 2021;130:80-97. [PMID: 34118448 DOI: 10.1016/j.actbio.2021.06.004] [Reference Citation Analysis]
6 Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology 2021;298:28-35. [PMID: 33170103 DOI: 10.1148/radiol.2020202903] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
7 Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Med 2021;3:142-50. [PMID: 33604544 DOI: 10.1016/j.xkme.2020.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
8 Martino F, Amici G, Rosner M, Ronco C, Novara G. Gadolinium-Based Contrast Media Nephrotoxicity in Kidney Impairment: The Physio-Pathological Conditions for the Perfect Murder. J Clin Med 2021;10:E271. [PMID: 33450989 DOI: 10.3390/jcm10020271] [Reference Citation Analysis]